SCHEMBL5374248

SCHEMBL5374248

Cc1ccc(NC(C)C)cc1Br

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 3/20 0.41
ALDH1A1 P00352 6/20 0.41
KDM4E B2RXH2 2/20 0.41
L3MBTL1 Q9Y468 2/20 0.41
TSHR P16473 2/20 0.41
LMNA P02545 1/20 0.41
CYP3A4 P08684 1/20 0.41
THRB P10828 1/20 0.41
ALOX15 P16050 1/20 0.41
ALOX12 P18054 1/20 0.41
RECQL P46063 1/20 0.41
ATM Q13315 1/20 0.41
HSD17B10 Q99714 1/20 0.41
NPC1 O15118 2/20 0.40
RAB9A P51151 2/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
POLB P06746 1/20 0.40
HPGD P15428 5/20 0.39
MEN1 O00255 2/20 0.38
KMT2A Q03164 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL879876 0.83 CYP3A4 (0.46) TDP1ALDH1A1KDM4EL3MBTL1TSHR
SCHEMBL5299443 0.80 TDP1 (0.46) TDP1ALDH1A1KDM4EL3MBTL1TSHR
Ammonia Solution, Strong SCHEMBL28135606 0.78 TDP1 (0.44) TDP1ALDH1A1KDM4EL3MBTL1TSHR
SCHEMBL13727629 0.78 ABL1 (0.47) TDP1ALDH1A1L3MBTL1TSHRLMNA
SCHEMBL3720647 0.78 ALOX15 (0.45) TDP1ALDH1A1L3MBTL1TSHRLMNA
SCHEMBL11798061 0.77 TDP1 (0.43) TDP1ALDH1A1L3MBTL1TSHRLMNA
SCHEMBL11206673 0.76 FPR2 (0.47) TDP1ALDH1A1KDM4ELMNANPC1
SCHEMBL11206672 0.76 FPR2 (0.47) TDP1ALDH1A1KDM4ELMNANPC1
SCHEMBL14267828 0.76 NPC1 (0.43) TDP1ALDH1A1KDM4EL3MBTL1TSHR
SCHEMBL14268251 0.75 ALDH1A1 (0.44) TDP1ALDH1A1L3MBTL1TSHRLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7304071-B2 Protein kinase inhibitors and uses thereof VERTEX PHARMACEUTICALS INCORPORATED (US) 2007-12-04 US disclosed
EP-1546117-A2 PROTEIN KINASE INHIBITORS AND USES THEREOF Vertex Pharmaceuticals Incorporated (US) 2005-06-29 EP disclosed
US-20040106615-A1 Protein kinase inhibitors and uses thereof VERTEX PHARMACEUTICALS INCORPORATED 2004-06-03 US disclosed
WO-2004016597-A2 PROTEIN KINASE INHIBITORS AND USES THEREOF VERTEX PHARMACEUTICALS INCORPORATED (US) 2004-02-26 WO disclosed
EP-1228042-A2 TETRAHYDROQUINOLINE DERIVATIVES HAVING RETINOID-LIKE BIOLOGICAL ACTIVITY Allergan Sales, Inc. (US) 2002-08-07 EP disclosed
WO-2001012606-A2 TETRAHYDROQUINOLINE DERIVATIVES HAVING RETINOID-LIKE BIOLOGICAL ACTIVITY ALLERGAN SALES, INC. (US) 2001-02-22 WO disclosed
US-6127382-A AN ANTIPROLIFERATIVE AGENT FOR TREATING SKIN-RELATED DISEASES, AN ANTITUMOR AGENT TREATING CANCER, AN ANTIINFLAMMATORY AGENT TREATING PULMONARY FIBROSIS, ILEITIS, COLITIS AND KROHN'S DISEASE ALLERGAN SALES, INC. (US) 2000-10-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040106615-A1 Protein kinase inhibitors and uses thereof JAK1, RAF1, PRKCQ TDP1 1696/4885ALDH1A1 4492/4885KDM4E 1127/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.